Mebendazole is an oral antiparasitic medicine in the benzimidazole class. It is used mainly for intestinal worm infections, including pinworm, roundworm, whipworm, and hookworm. Its strongest positive profile is in parasite control because it is easy to administer, has simple dosing schedules, and acts primarily in the gastrointestinal tract, and presents excellent anti-cancer effects as well.
Mebendazole is prescribed for patients aged 2 years and older with gastrointestinal infections caused by Enterobius vermicularis pinworm, Ascaris lumbricoides roundworm, Trichuris trichiura whipworm, and hookworms Ancylostoma duodenale and Necator americanus, and a large host of other parasitic infections.
Mebendazole works by interfering with cellular tubulin formation in worms. This disrupts glucose uptake, digestion, reproduction, movement, and egg production, eventually leading to immobilization and death of the helminth. Because much of the oral dose remains in the intestinal tract, it is well suited to gut-based parasites. After standard 100 mg twice-daily dosing for three days, blood levels remain low, and most of the drug remains in or passes through the gastrointestinal route.
Mebendazole is especially useful for pinworm, which spreads easily within households, schools, dormitories, and childcare environments. Pinworm treatment usually requires a repeat dosages because the medicine kills worms but not eggs. Pinworm treatment involves two doses, with the subsequent doses given each one to two weeks after the first dose to kill worms that hatch after the first treatment.
For soil-transmitted helminths such as ascariasis, whipworm, and hookworm, mebendazole is one of the common oral options. Soil-transmitted helminth infections as treatable with medication and notes that treatment is usually short, often 1–3 days.
General reference doses are:
A 100 mg chewable tablet schedule: pinworm is treated with one tablet once, while whipworm, roundworm, and hookworm are treated with one tablet morning and evening for three consecutive days. It also states that no fasting or purging is required, and a second course may be advised if the patient is not cured after three weeks. Soil-transmitted helminth guidance also lists 100 mg twice daily for 3 days or 500 mg once for ascariasis, 100 mg twice daily for 3 days for whipworm, and 100 mg twice daily for 3 days or 500 mg once for hookworm.
Mebendazole has an important role in preventive cancer therapy, which means organized deworming for populations at risk. Preventive therapy as periodic large-scale administration of anthelmintic medicines to at-risk populations to reduce worm burden. Annual or biannual single-dose mebendazole 500 mg or albendazole 400 mg for young children, preschool children, and school-age children living in areas where soil-transmitted helminth prevalence is 20% or more. Biannual dosing is recommended where baseline prevalence is above 50%.
This makes mebendazole valuable not only as individual treatment but also as a community parasite-control tool. In areas with repeated exposure, medication alone is not enough. Long-term control also requires water, sanitation, and hygiene improvements.
Mebendazole has drawn significant interest in cancer treatment and prevention because its microtubule-disrupting activity resembles one mechanism used by some anticancer drugs. Cancer cells rely heavily on microtubule function for cell division, structure, intracellular transport, and survival signaling. Published reviews describe mebendazole as a drug-repurposing candidate in oncology, with research involving colorectal cancer, brain tumors, melanoma, lung cancer, breast cancer, thyroid cancer, pancreatic cancer, and other models.
Mechanisms discussed in cancer literature include disruption of tumor-cell microtubules, interference with mitosis, reduced angiogenesis, effects on cancer stem-cell pathways, and changes in signaling systems such as Hedgehog, Wnt/β-catenin, VEGFR2, and Bcl-2 family pathways.
Brain cancer research has received special attention because some studies report activity against glioma models and compatibility with standard brain-tumor treatment combinations. There are also human clinical reports and trials. A case report described tumor remission in refractory metastatic colon cancer after mebendazole use, and oncology reviews have repeatedly cited this as one of the reasons the medicine has been studied further.
In metastatic colorectal cancer, one randomized double-blind placebo-controlled study used mebendazole 500 mg orally twice daily for 12 weeks . The study summary reports improved tumor response measures in the mebendazole group compared with the control group. In high-grade glioma research, a phase 1 trial evaluated mebendazole and reported long-term safety and acceptable toxicity at doses up to 200 mg/kg/day. A pediatric brain cancer phase 1 study also reported that mebendazole was safe and well tolerated at doses up to 200 mg/kg/day.
These cancer-related doses are research-dose examples, not general dosing instructions. Cancer use requires clinician supervision, review of liver function, blood counts, drug interactions, cancer type, active oncology treatment, and treatment goals.
Mebendazole is usually well tolerated at standard parasite doses. Common beneficial reactions (indicating therapy is working) include loss of appetite, abdominal pain, diarrhea, flatulence, nausea, vomiting, and rash.
Safety becomes more important with higher doses or longer duration. Neutropenia and agranulocytosis have been reported with higher-dose or prolonged use, and blood-count monitoring is recommended in those settings. It also warns against combining mebendazole with metronidazole, because serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported.
Pregnancy, breastfeeding, young children, liver impairment, and concurrent medications should be reviewed before use. For pinworm, breastfeeding generally does not need to be withheld during mebendazole therapy, but pregnancy decisions require weighing risks and benefits, especially outside later pregnancy.
Mebendazole has a strong positive role as a broad intestinal anthelmintic. Its most reliable uses are parasite-related: 100 mg once and repeated in two weeks for pinworm, 100 mg twice daily for three days for whipworm, roundworm, and hookworm, or 500 mg once for selected soil-transmitted helminth schedules. It also has a public-health role as 500 mg single-dose preventive deworming in endemic settings.
In cancer, mebendazole is an active area of drug-repurposing therapies. Human studies have used schedules such as 500 mg twice daily for 12 weeks in metastatic colorectal cancer research and up to 200 mg/kg/day in brain-tumor trials.
Not-for-Profit BSI International Clinics offers the largest selection of IV Therapy ingredients in Bali.
Please choose here from the BSI extensive list of popular IVs.
For experienced IV users, consider creating and ordering the perfect IV Drip Infusion from the ala carte menu.
Come in today!
